Policy | August 09, 2021
China NMPA approves phase II clinical trial of ASC40
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
The company expects revenue growth of 10-15 per cent in the US
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
It is part of the company’s pain/analgesics portfolio of OTC products
Startup receives US $ 5 million in first round of funding
Subscribe To Our Newsletter & Stay Updated
